All lobbying filings

Novo Nordisk Inc.

Novo Nordisk Inc. filed a Q2 report for Novo Nordisk Inc. on July 20, 2026.

Lobbying for Novo Nordisk Inc.

As filed: NOVO NORDISK INC. for NOVO NORDISK INC.

All filings by Novo Nordisk Inc. · Everything Novo Nordisk Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$1,300,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

ANSLEY RHYNE

Previously held: Legislative Assistant, Senator Marco Rubio
ROSALYN KUMAR New on this filing

Previously held: Deputy Chief of Staff, Rep. Debbie Wasserman Schultz; Tax Counsel, Senator Stabenow

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 11

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding.

Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill.

Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing.

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding.

Taxation/Internal Revenue Code

International and corporate tax issues.

Tariff (miscellaneous tariff bills)

Tariffs and trade policy.

Bills named in this filing 1

S. 150
Affordable Prescriptions for Patients Act of 2023

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.